Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 10Stomach Neoplasms 8Prostatic Neoplasms 7Squamous Cell Carcinoma of Head and Neck 4Lung Neoplasms 4Gastrointestinal Neoplasms 3Neoplasms 2Head and Neck Neoplasms 2HER2-positive Breast Cancer 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stage I Prostate Adenocarcinoma AJCC v7 1Squamous Cell Non-small Cell Lung Cancer 1Recurrent Squamous Cell Lung Carcinoma 1Recurrence 1Progression Free Survival 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lymphoid Interstitial Pneumonia 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1HER2-negative Breast Cancer 1FGFR1 Gene Amplification 1

Interventions

Paclitaxel 1Epirubicin 1Docetaxel 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × HER2-negative Breast Cancer × Docetaxel × Clear all
NCT04576143 2021-08-12

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2/3 Recruiting
260 enrolled
Breast

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡